Savara Inc
NASDAQ:SVRA
Savara Inc
Other Equity
Savara Inc
Other Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Savara Inc
NASDAQ:SVRA
|
Other Equity
-$984k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Equity
-$1.9B
|
CAGR 3-Years
13%
|
CAGR 5-Years
12%
|
CAGR 10-Years
1%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Equity
$132m
|
CAGR 3-Years
15%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-8%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Equity
-$66m
|
CAGR 3-Years
56%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Equity
$120.7m
|
CAGR 3-Years
96%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
61%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Equity
-$7.9m
|
CAGR 3-Years
33%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Savara Inc
Glance View
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is headquartered in Austin, Texas and currently employs 22 full-time employees. The company went IPO on 2001-06-25. The firm is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim an inhaled formulation of recombinant human GM-CSF, is being developed for the treatment of aPAP. Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the build-up of surfactant in the alveoli or air sacs of the lungs.
See Also
What is Savara Inc's Other Equity?
Other Equity
-984k
USD
Based on the financial report for Dec 31, 2024, Savara Inc's Other Equity amounts to -984k USD.
What is Savara Inc's Other Equity growth rate?
Other Equity CAGR 1Y
-113%
Over the last year, the Other Equity growth was -113%.
You don't have any saved screeners yet